News | Ultrasound Imaging | October 28, 2020

Ultrasounds Show Impact of COVID-19 on the Heart

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health S

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health System

October 28, 2020 — Cardiac ultrasounds (also known as echocardiograms) are providing a view of the heart and the impact of the COVID-19 virus on patients. A new study by researchers at Icahn School of Medicine at Mount Sinai identifies different types of cardiac structural damage experienced by COVID-19 patients after cardiac injury that can be associated with deadly conditions including heart attack, pulmonary embolism, heart failure, and myocarditis. These abnormalities are associated with higher risk of death among hospitalized patients. The findings, published the October 26 issue of the Journal of the American College of Cardiology, offer new insights that may help doctors better understand the mechanism of cardiac injury, leading to quicker identification of patients at risk and guidance on future therapies.

"Early detection of structural abnormalities may dictate more appropriate treatments, including anticoagulation and other approaches for hospitalized and post-hospitalized patients," said author Valentin Fuster, M.D., Ph.D., Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital.

The international, retrospective study expands on Mount Sinai's previous research showing that myocardial injury (heart damage) is prevalent among patients hospitalized with COVID-19 and is associated with higher risk of mortality. That study focused on the patients' levels of troponin--proteins that are released when the heart muscle becomes damaged--and their outcomes (higher troponin levels mean greater heart damage).

This new work looked at the presence of cardiac troponin elevations in combination with the presence of echocardiographic abnormalities, and found that the combination was associated with worse prognosis and mortality than troponin elevations alone.

"This is one of the first studies to provide detailed echocardiographic and electrocardiographic data in hospitalized patients with COVID-19 and laboratory evidence of myocardial injury," explained first and corresponding author Gennaro Giustino, M.D., Cardiology Fellow at The Mount Sinai Hospital. "We found that among COVID-19 patients who underwent transthoracic echocardiography, these cardiac structural abnormalities were diverse and present in nearly two-thirds of patients."

Researchers looked at transthoracic echocardiographic (TTE) and electrocardiographic (ECG) scans of 305 adult patients with confirmed positive COVID-19 admitted to four New York City hospitals within the Mount Sinai Health System (The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Queens, and Mount Sinai Beth Israel), Elmhurst Hospital in Queens, and two hospitals in Milan, Italy, between March and May 2020. Median age was 63 years and 67.2 percent were men. 190 patients (62.6 percent) had evidence of myocardial injury; 118 of them had heart damage at the time of hospitalization admission and 72 developed myocardial injury during hospitalization. Researchers found that patients with myocardial injury had more electrocardiographic abnormalities, higher inflammatory biomarkers, and an increased prevalence of TTE abnormalities when compared to patients without heart injury.

Abnormalities were diverse, with some patients exhibiting multiple abnormalities. 26.3 percent had right ventricular dysfunction (which can be associated with pulmonary embolism and severe respiratory failure), 23.7 percent had regional left ventricular wall motion abnormalities (which can be associated with heart attacks), 18.4 percent had diffuse left ventricular dysfunction (which can be associated with heart failure/myocarditis), 13.2 percent had grade II or III diastolic dysfunction (a condition leading to stiffer cardiac chambers), and 7.2 percent had pericardial effusions (extra fluid around the heart that causes abnormal pumping of the heart).

The study went on to look at in-hospital mortality and troponin elevation. It shows that troponin elevation was 5.2 percent among patients who did not have heart injury, compared to 18.6 percent for patients with myocardial injury but without echocardiographic abnormalities, and 31.7 percent for patients with myocardial injury who also had echocardiographic abnormalities. Researchers adjusted for other major complications from COVID-19 including shock, acute respiratory distress syndrome, and renal failure.

"Our study shows that an echocardiogram performed with appropriate personal protection considerations is a useful and important tool in early identification of patients at greater risk for COVID-19-related cardiac injury, who may benefit from a more aggressive therapeutic approach earlier in their hospitalization," said corresponding author Martin Goldman, M.D., Arthur M. and Hilda A. Master Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai. "Additionally, because this is a new disease with lingering symptoms, we plan on following these patients closely using imaging to evaluate the evolution and hopefully resolution of these cardiac issues."

"Echocardiograms have shown to be invaluable in providing critical information on patients who present with multiple cardiac complaints. Echocardiography is the only imaging modality that can be taken to the bedside and safely used for patients including those on ventilators," said Lori Croft, M.D., Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai and Director of the Echocardiography Laboratory at The Mount Sinai Hospital. "Our findings will help guide care of Covid-19 patients during a critical time."

For more information: www.mountsinai.org

Related Content

Study conducted by medical AI startup Lunit and Massachusetts General Hospital, published in JAMA Network Open - When used as a second reader, the AI algorithm may help detect lung cancer
News | Artificial Intelligence | November 26, 2020
November 26, 2020 — A recent study published in ...
Vital is hosting demonstrations and educational content from industry experts
News | Enterprise Imaging | November 26, 2020
November 26, 2020 — Vital, a Canon Group company, alongside
Philips Smart diagnostic systems empower patients and staff with more definitive diagnostic and interventional radiology studies, optimized workflows, enhanced efficiency and operational excellence
News | Artificial Intelligence | November 25, 2020
November 25, 2020 — Philips announced its participation in the RSNA...
ASG well positioned for growth as healthcare marketplace continues to evolve 

Allan Klotsche

News | Radiology Imaging | November 24, 2020
November 24, 2020 — Alpha Source Group (ASG), a comprehensive next-generation services partner, has named...
 Lunit, a leading medical AI software company, will be joining the 106th Radiological Society of North America (RSNA) this year, presenting its AI solutions for chest X-ray and mammography at partner booths.
News | Artificial Intelligence | November 24, 2020
November 24, 2020 — Lunit, a leading medical AI software company, will be joining the 106th...
New multimodality virtual imaging command center enables real-time, remote collaboration to broaden expertise between technologists, radiologists and imaging operations teams across multiple sites via private, secure telepresence capabilities
News | Information Technology | November 24, 2020
November 24, 2020 — Philips announced commercial launch of the industry’s first vendor-neutral, multimodality, radiol
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...